Stanton Mehr (@StanMehr) profile picture

For 30 years, Stan has been writing, editing, and presenting on a variety of health care topics, including biosimilars through his company and BR&R website.

Joined February 2016
Phase 3 Trials Cut Short, Lupin's First Biosimilar, Tyruko Launches, and More! - mailchi.mp/263f0e91d1c2/a-pr…
1
40
I am less inclined these days to post on the X/Twitter platform, based on the actions of the platform's owner and his allies and their effect on this country. I will be shutting down my account shortly. Please see my #biosimilar posts on LinkedIn and on biosimilarsrr.com.
1
4
97
Partners @alvotechpr and @Teva announced that the FDA has accepted the first #biosimilar application for a candidate to compete with #Simponi (reference manufacturer, @JNJNews. An FDA decision could be made in Q4 2025. #golimumab @BioTheraSolutions wp.me/p7gt6c-82O
3
121
I look forward to attending the upcoming #Access2025 in only 2 weeks! Join me and a solid line-up of speakers talking about #biosimilars and #generics and maybe even get a clue as to how the new administration will affect the industry.
🚨 DON'T MISS OUT. Discounted hotel rates expire TODAY. Register for #Access2025 now to join top industry leaders and shape the future of #generics and #biosimilars: access.accessiblemeds.org
1
2
191
At the end of April, I'll be chairing a panel at the upcoming Festival of Biologics USA meeting in San Diego on a discussion on the private-labeling trend and #marketaccess implications. I look forward to seeing you there. #festivalofbiologicsUSA
1
67
The onset of the new year brings with it the first major event in 2025: @Amgen 's launch of the first #ustekinumab biosimilar. However, several important developments in #biosimilars will be worth watching. Here are some of the most notable. wp.me/p7gt6c-7Z8
1
74
Once introduced as a "pure-play" biosimilar company, the book is now closed on @Coherus_Bio's #biosimilar aspirations. The acquisition by Intas (i.e., its @AccordBioPharma specialty division) of #Udenyca for $558 million will bolster its portfolio. wp.me/p7gt6c-7UT
3
137
On December 2, @BioconBiologics announced that it had received #FDA approval for #Yesintek, the sixth authorized #Stelara #biosimilar (so far). Biocon will launch the latest #ustekinumab biosimilar by Feb 22, 2025. wp.me/p7gt6c-7UC
2
156
Will #PBM private-labeling ventures save or sink the #biosimilar industry? This question should be closely examined by all stakeholders interested in ensuring biosimilar competition into the future. #adalimumab #ustekinumab #tocilizumab wp.me/p7gt6c-7TA
1
6
146
We're looking forward to the start of #GlobalBiosimilarsWeek, November 11-14. An international partnership devoted to accelerating access to less-costly, highest-quality #biosimilar medicines around the globe, #GBW will be filled with webinars and news on biosimilar issues.
5
140
At October’s #GRxBiosims meeting, we sat down with Joshua Salsi, @BioconBiologics' Head of North America, to discuss how the organization faces the rapidly evolving regulatory and #biosimilar market access environment. #ASP #pharmacybenefit #medicalbenefit wp.me/p7gt6c-7Qs
1
73
In Biosimilars Review & Report, we're introducing "Biosimilar Manufacturer Profiles" to increase your exposure and reach. It will include info on your company, with approved products, pipeline, and company-related news. Contact [email protected] for details.
98
We’re thrilled at BR&R to be partners in the #GlobalBiosimilarsWeek initiative. Held November 11-15, #GBW is an international partnership devoted to accelerating access to less-costly, highest-quality #biosimilar medicines now and in the future. #IGBA
4
79
On October 22, the federal appeals court denied @Regeneron’s request for an injunction against @Amgen pending appeal, which would have forestalled the biosimilar maker’s launch of #Pavglu, its biosimilar version of #Eylea. #aflibercept #biosimilars wp.me/p7gt6c-7PQ
1
2
141
At this week’s #GRxBiosims 2024, a panel tackled whether interchangeability matters today. An IC designation has not yet been utilized widely in any drug category to enable a quick shift away from the reference drug. @Teva @NACDS @amcporg @VizientInc wp.me/p7gt6c-7Pd
1
4
145
Nick Adolph of @IQVIA at #GRxBiosims We're still at 10% uptake for adalimumab biosimilars 20 months postlaunch, but the volume of biosimilars has decreased, with rising use of @abbvie's #Skyrizi and #Rinvoq. Branded #Humira still owns 81% marketshare. @Sandoz_Global #AAM
4
2
6
658
Excellent panel at #GRxBiosims 2024 on clinical validation studies that might be needed for administration devices in biosimilar/interchangeables! The studies raise fascinating questions on need, population recruitment, and more. #FDA @Teva @Amneal @Sandoz_Global
3
95